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Abstract: Natural killer (NK) cells’ major role in the control of viruses is to eliminate 
established infected cells. The capacity of NK cells to kill virus-infected cells is dependent 
on  the  interactions  between  ligands  on  the  infected  cell  and  receptors  on  the  NK  cell 
surface. Because of the importance of ligand-receptor interactions in modulating the NK 
cell cytotoxic response, HIV has developed strategies to regulate various NK cell ligands 
making the infected cell surprisingly refractory to NK cell lysis. This is perplexing because 
the HIV-1 accessory protein Vpr induces expression of ligands for the NK cell activating 
receptor, NKG2D. In addition, the accessory protein Nef removes the inhibitory ligands 
HLA-A  and  -B.  The  reason  for  the  ineffective  killing  by  NK  cells  despite  the  strong 
potential to eliminate infected cells is due to HIV-1 Vpu’s ability to down modulate the  
co-activation ligand, NTB-A, from the cell surface. Down modulation of NTB-A prevents 
efficient NK cell degranulation. This review will focus on the mechanisms through which 
the HIV-1 accessory proteins modulate their respective ligands, and its implication for NK 
cell killing of HIV-infected cells.  
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1. Natural Killer Cells Control Virus Production 
An  important  first  line  of  defense  against  viruses  involves  natural  killer  (NK)  cells.  Unlike 
cytotoxic T-lymphocytes, which also destroy virus-infected cells, NK cells respond to infected cells 
without  prior  exposure  to  infected  cells  or  their  components.  Hence,  the  action  of  NK  cells  to 
immediately eliminate virus-infected cells and prevent the spread of the virus is essential during the 
early stages of viral infections since adaptive anti-viral immune responses are not fully developed. The 
importance of NK cells in controlling virus infections, in vivo, was initially shown in mice depleted of 
NK cells. Without NK cells, infected mice are unable to control a plethora of viruses [1–3]. Humans 
lacking or having dysfunctional NK cells develop fatal disseminated herpes infections [4–8]. Since NK 
cells  are  effective  at  eliminating  virus-infected  cells,  many  viruses that  chronically  infect  humans 
utilize strategies to avoid detection and elimination by NK cells [9–12]. 
NK cells  control viruses in  one  of three  ways:  (1)  by directed release  of the contents  of lytic 
granules onto infected cells, (2) by expressing ligands (i.e., Fas ligand and TRAIL) that engage death 
receptors on infected cells, and (3) by secreting cytokines (e.g., IFN-, MIP-1) that impede or prevent 
virus replication [13–17]. In fact, secretion of IFN- by NK cells has been shown to enhance MHC 
class I expression on antigen presenting cells to enhance CD8+ T-cell recognition of infected cells [18]. 
NK cell cytotoxic granules contain perforin and granzymes. Perforin forms pores on the target cell, and 
granzymes enter through the pores and initiate apoptosis within the target cell [19,20]. The directed 
release of the contents of cytolytic granules (degranulation) is triggered by two distinct mechanisms. 
Antibody-dependent cellular cytotoxicity (ADCC) results in the release of perforin and granzymes 
when antibody-coated cells engage the low affinity receptor for IgG, CD16 (or FcγRIIIa), on NK  
cells [21]. Secondly, engagement of germline-encoded receptors on NK cells by their invariant ligands 
on  the  target  cells  regulates  degranulation  [22–25].  This  review  will  focus  on  the  latter  NK  cell 
response.  In  particular,  we  will  discuss  how  HIV-1-infected  cells  manipulate  surface  ligands  that 
trigger NK receptors essential in regulating degranulation. 
2. Polarization of Lytic Granules in NK Cells Requires Stable Interactions with Target Cells 
Directed degranulation by NK cells ensures that a specific, infected cell is killed leaving healthy 
neighboring  cells  unharmed  [25,26].  Polarization  of  lytic  granules  towards  the  target  cells  and 
subsequent degranulation requires the participation of three major classes of receptors: (1) adhesion 
receptors, (2) activating receptors, and (3) co-activating receptors [26]. The initial step of cytolysis 
involves  a  loose  association  (Kd  =  ~  100  M)  between  target  cells  and  NK  cells  that  require 
carbohydrate Ag Lewis
X (e.g., CD15, Gal-1-4 GlcNAc 1-3Fuc) on target cells to interact with CD2 
or selectins on NK cells [27]. Loose interactions between Ag Lewis
X and lectin-like receptors such  
as CD94 and NKG2D may allow for the NK cell to slow down and initiate longer contact with its 
target [28]. This loose adhesion between NK and target cells is soon followed by a stable interaction 
involving  integrins  (e.g.,  lymphocyte  function-associated  antigen  (LFA)-1)  on  NK  cells  and  the 
intercellular  adhesion  molecules  (ICAM)  family  on  target  cells  [29,30].  Once  a  stable  interaction 
occurs, ―firm‖ adhesion follows  [31,32]. ―Firm‖ adhesion involves a conformation change from a 
―closed‖ low affinity (Kd = ~ 100 M) state to an ―open‖ configuration in which the integrins bind to Viruses 2011, 3                         
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ICAMs with higher affinity (Kd = ~ 0.4 M) [33,34]. The engagement of activating receptors on the 
NK cell with their ligands on the target cell enhances the ―open‖ configuration state [34]. 
Following the binding of integrins on NK cells to ICAMs on target cells, several events occur 
within the NK cells which brings the cytolytic granules towards the target cell  [35]. Initially, the 
cytotoxic granules migrate in the direction of the microtubule-organizing center (MTOC) towards the 
minus  ends  of the microtubules  found at the MTOC  [36]. This  is followed by actin cytoskeleton 
rearrangement that recruits activating receptors into lipid rafts. The clustering of activation receptors 
between the points of contact of the NK cell and its target forms the immunological synapse [37–39]. 
Following  recruitment  of  activation  receptors  to  lipid  rafts,  the  MTOC  containing  lytic  granules 
polarizes toward the immunological synapse due to the reorganization of the actin network [35,40]. 
The  consequence  of  the  MTOC  containing  granules  polarizing  to  the  synapse  will  allow  for  the 
eventual release of cytotoxic granules in an area adjacent to the activating receptors (Figure 1).  
Figure 1. Coordinated events occur when forming an immunological synapse. Directed 
release of cytotoxic granules requires coordinated series of events. Synapse formation is 
accomplished following engagement of lymphocyte function-associated antigen (LFA)-1 
on natural killer (NK) cells with intercellular adhesion molecules (ICAMs) on the target. 
Immunological synapse contains a ―lipid raft‖ domain (shown in black) containing activating 
receptors. This is adjacent to a section of the plasma membrane allowing for the unobstructed 
release of perforin and granzymes, into the space between the NK cell and target. 
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3. Degranulation Follows Engagement of NK Cell Activating Receptors 
While integrin engagement leads to polarization of lytic granules towards the target cell, triggering 
integrins alone is insufficient for NK cells to degranulate [41]. ―Activating‖ receptors (aNKRs) on NK 
cells being bound by their respective ligands on the target cell are required to elicit an NK cell to 
degranulate [42]. aNKRs lack signaling motifs in their intracellular domains. Instead, these receptors 
associate non-covalently with adaptor proteins through a charged residue in the activating receptor 
transmembrane region [24,43]. aNKRs (e.g., NKp30, NKp44, NKp46) and the killer immunoglobulin-
like receptors with short cytoplasmic tails (e.g., KIR2DS1, KIR3DS1) interact with adaptor proteins 
containing immunoreceptor tyrosine-based activation motifs (ITAMs), defined as YXX(L/I)X6–8YXX(L/I) 
(where X6–8 are 6 to 8 residues between the two tyrosines) [22,44–48]. ITAM containing adaptor 
molecules include: DAP12, FcεRIγ, and CD3δ [25,49]. These adaptor proteins become phosphorylated 
by tyrosine kinases such as Syk and ZAP-70 allowing for NK cell cytotoxicity (See Table 1 for list of 
aNKRs) [50].  
A  second  group  of  aNKRs  does  not  associate  with  adaptor  molecules  containing  ITAMs  [24].  
For example, NKG2D associates with the adaptor protein DAP10, which contains an YXXM motif. 
After  phosphorylation,  DAP10  recruits  phosphatidylinositol-3-kinase  (PI3K)  and  growth  factor 
receptor-bound protein (Grb)-2 [51,52].  
Table 1. Natural Killer Cell Activation Receptors. 
Name  Ligand  Adaptor Protein 
NKp30  Unknown   
NKp44  Unknown  DAP12 
NKp46  Unknown   
CD158h/KIR2DS1  HLA-C  DAP12 
CD158i/KIR2DS4  HLA-Cw4  DAP12 
CD158e2/KIR3DS1  Unknown  DAP12 
CD158j/KIR2DS2  Unknown  DAP12 
NKG2D  ULBP-1-6, MIC-A,-B  DAP10 
CD16  IgG   
Modified from [25]. 
4. Phospholipase C-γ is the Key Mediator for NK Cell Degranulation  
Engagement of both adhesion and activating receptors lead to recruitment and phosphorylation of 
Vav1, a guanine exchange factor [53]. Vav1 ultimately regulates actin cytoskeleton rearrangement for 
polarization of granules and activation receptor clustering [39]. Phosphorylation of Vav1 ultimately 
leads to phosphorylation of phospholipase C-γ (PLCγ) following LFA-1 and/or NKG2D engagement 
(Figure 2). Phosphorylated PLCγ in turn hydrolyzes phosphatidylinositol 4, 5 bisphosphate (PIP2) to 
inositol  1,  4,  5  trisphosphate  (IP3)  and  diacylglycerol  (DAG)  [54,55].  DAG  recruits  mammalian 
uncoordinated (Munc) 13-4, an essential component of the vesicle fusion complex crucial for regulated 
degranulation,  to  the  plasma  membrane  [56].  Vesicle  fusion  to  the  plasma  membrane  is  further 
facilitated by Rab27a, a Rab GTPase. Rab27a is recruited to the cell surface after LFA-1 engagement 
allowing for the granules to dock with Munc 13-4 at the plasma membrane [57]. IP3 binds to inositol Viruses 2011, 3                         
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trisphosphate receptor on the endoplasmic reticulum membrane and opens a calcium channel resulting 
in the release of calcium into the cytoplasm [58]. Calcium is necessary for the final fusion between the 
cytolytic granule and plasma membrane [59]. 
Figure 2. Two activating signals are required to initiate NK cell degranulation. Signals 
from  activating  (NKG2D)  and  co-activating  receptor  (NTB-A)  converge  to  activate 
phospholipase-Cγ (PLCγ). Vav1, a guanine exchange factor, is able to phosphorylate PLCγ 
when triggered by activating receptors. However, engagement of activating receptors also 
phosphorylates c-Cbl, an ubiquitin ligase that negatively regulates Vav1. To overcome this 
inhibition, a co-activating receptor must be engaged to phosphorylate sufficient PLCγ to 
trigger degranulation. Degranulation is mediated by the cleavage of phosphatidylinositol 
into diacylglycerol (DAG) and inositol 1,4,5 triphosphate (IP3). DAG recruits key proteins 
to the plasma membrane to initiate fusion of the granule and plasma membrane. IP3, once 
cleaved, binds its receptor, IP3 receptor, on the membrane of the endoplasmic reticulum to 
open calcium channels. Ca
2+ influx allows for the exocytosis of the cytolytic granules. 
Inhibitory  receptors  such  as  the  KIRs  can  recruit  phosphatases  that  lead  to  the 
dephosphorylation of Vav1. However, the KIRs also have the ability to activate tyrosine 
kinases like c-Abl leading to the inhibition of actin rearrangement. 
 
 
The amount of Vav1 phosphorylation induced by integrins and activating receptor(s) is insufficient 
to lead to degranulation. However, there may be a sufficient amount of phosphorylated Vav1 to lead to 
granule  polarization  and  immunological  synapse  formation.  This  is  because  Vav1  is  negatively 
regulated by the ubiquitin ligase c-Cbl. c-Cbl is induced upon engagement of an activating receptor 
(e.g., NKG2D), to dampen NK cell cytotoxicity, which in turn, leads to Vav1’s ubiquitination and 
proteosomal degradation. The loss of Vav1 decreases the levels of phosphorylated PLCγ and prevents Viruses 2011, 3                         
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NK cell degranulation [55]. To overcome the effects of c-Cbl’s inhibition of Vav1, NK cells require 
concomitant engagement of activating and co-activating receptors [55]. 
Co-activation receptors include the CD2 family of activating receptors (e.g., 2B4, CRACC, NTB-A) 
(See  Table  2  for  list  of  caNKR)  [60–62].  The  CD2  family  of  receptors  associates  with  signaling 
lymphocyte  activation  molecule  (SLAM)-associated  protein  (SAP)  to  induce  cellular  cytotoxicity  
[63–65]. When these receptors bind their respective ligands, tyrosine residues in the cytoplasmic tail 
become phosphorylated allowing for the recruitment of SAP. SAP binds to the tyrosine kinase, Fyn, 
through an arginine at position 78 in its SH2 domain [66,67]. Once bound to SAP, Fyn phosphorylates 
both  the  SLAM-family  receptor  as  well  as  molecules  such  as  PLCγ  to  induce  the  NK  cell  to 
degranulate [68]. More importantly, degranulation of resting NK cells requires at least a specific pair 
of activating and/or co-activating receptors to be engaged. Such pairs include NKG2D and NKp46, 
NKp46 and DNAM-1, and 2B4 and DNAM-1. However, combinations such as NKG2D and DNAM-1 
do not result in NK cell degranulation [42].  
Table 2. Natural Killer Cell co-Activation Receptors. 
Name  Ligand  Adaptor Protein 
NTB-A  NTB-A  SAP/EAT-2 
DNAM-1  CD155/CD112  Protein Kinase C 
CRACC  CRACC  EAT-2 
2B4  CD48  SAP 
Modified from [25]. 
5. Inhibitory Receptors Regulate Cytoskeleton Rearrangement and Synapse Formation 
In addition to activation receptors, NK cell responses are regulated by inhibitory receptors (iNKRs) 
present on NK cells. iNKRs contain immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in the 
cytoplasmic domain defined by the sequence (I/L/V/S)XYXX(L/V)  [25]. Once the ITIMs become 
phosphorylated they recruit phosphatases such as Src homology region 2 domain containing phosphatase 
(SHP)-1 and SHP-2 [69,70]. These phosphatases lead to the dephosphorylation of signaling molecules 
involved  in  calcium  influx,  actin  rearrangement,  and  granule  polarization  initiated  by  adhesion 
receptors  [71–73].  Inhibitory  receptors  also  activate  kinases  such  as  c-Abl  which  play  a  role  in 
inhibiting actin rearrangement [74]. 
One major set of ligands to iNKRs is the major histocompatibility complex (MHC) class I molecules 
[45,75–77].  The  MHC-I  recognizing  families  of  iNKRs  are  the  killer-immunoglobulin  (Ig)-like 
receptors  (KIRs)  with  ITIM-containing  cytoplasmic  tails,  which  recognizes  HLA-A,  -B,  and  -C;  
the receptor pair of NKG2A and CD94, which recognizes HLA-E; and the interleukin-like transcript 
type  2  (ILT-2),  which  recognizes  multiple  HLA  molecules.  As  MHC  class  I  molecules  are 
constitutively  expressed  on  all  healthy  nucleated  cells,  iNKRs  recognition  of  their  MHC-I  ligand 
inhibits the NK cell’s ability to kill healthy ―self‖ cells. Many viruses down modulate MHC class I 
molecules on infected cells to avoid CD8+ T-cell responses [78]. However, MHC-I down modulation 
leaves the target cell susceptible to destruction by NK cells by removing inhibitory ligands [10,11]. 
Simply lacking or having impaired expression of MHC class I molecules is insufficient for NK cell 
lysis. NK cells will only degranulate and kill the infected cell after engagement of activating receptors. Viruses 2011, 3                         
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Moreover, NK cells are capable of degranulating target cells that have normal expression of MHC-I on 
its surface if activating receptors are engaged to overcome the inhibition [79]. 
 
6. HIV-1 Alters NK Cell Degranulation by Modulating Ligands to NK Cell Receptors 
Nearly 25 years ago NK cells were found to be inefficient at killing autologous HIV-1 infected 
primary  T-cells  [80–82].  However,  the  mechanism  to  explain  the  inability  of  NK  cells  to  lyse  
HIV-infected cells has only recently been discovered. Below we will discuss how HIV-1 gene products 
impact NK cell cytolytic function and ultimately how HIV-1 avoids destruction by NK cells.  
6.1. HIV-1 Vpr Induces Expression of Ligands for the NK Cell Activating Receptor NKG2D  
NKG2D is a type II transmembrane C-type lectin that associates with the adaptor protein DAP10 
[83,84]. It is expressed on all NK cells in the blood as well as subsets of CD8+ T-cells, γδ T-cells, and 
NKT  cells  [21].  NKG2D  ligands  include  the  MHC  class  I  polypeptide-related  sequence  (MIC)-A  
and -B, as well as the cytomegalovirus unique long 16-binding protein (ULBP)-1 thru -6 [85,86]. 
These ligands typically are not expressed on healthy cells; however, NKG2D ligands are expressed at 
relatively high levels on cells undergoing genotoxic stress [87]. DNA damage leads to NKG2D ligand 
expression through induction of the DNA damage sensor ataxia telangiectasia-mutated (ATM) and 
ataxia  telangiectasia-mutated  and  Rad  3-related  (ATR)  [87].  ATM  detects  double  stranded  DNA 
breaks,  whereas  ATR  detects  single  stranded  DNA  breaks,  typically  at  replication  forks  [88,89]. 
Activation  of  either  of  these  kinases  will  result  in  cell  cycle  arrest  and  subsequent  induction  of 
NKG2D ligands [90]. 
ATR and not ATM is phosphorylated and activated during HIV-1 infection by the viral protein Vpr 
[88,91]. One of the benefits of ATR’s induction for HIV-1 is to induce G2 cell cycle arrest. The long 
terminal repeat (LTR) of HIV-1 is highly active during the G2 phase of the cell cycle resulting in 
higher viral production [92–94]. It has been hypothesized that G2 cell cycle arrest is associated with 
Vpr binding to DCAF1, a substrate recognition subunit for an E3 ubiquitin ligase complex, through 
Vpr’s leucine rich motif from residue 60–68 (Figure 3). Vpr binds not only to DCAF1 but also an 
unknown cell cycle protein through an arginine at residue 80 of Vpr [95–97]. The Vpr complex in turn 
associates  with  the  E3  ubiqutin  ligase  complex,  Cullin  4a/damaged  DNA  binding  protein  I 
(Cul4a
DDB1/DCAF1) [98]. When the unknown cell cycle protein is ubiquitinated and destroyed by the E3 
ubiquitin  ligase  complex,  G2  arrest  is  induced  and  ATR  becomes  phosphorylated  [98].  ATR’s 
phosphorylation through Vpr not only results in G2 arrest, but also leads to the expression NKG2D 
ligands.  Vpr  leads  to  ULBP-1  and  -2  expression  but  not  ULBP-3  through  -6,  or  MIC-A  and  -B 
[99,100].  The  specificity  of  NKG2D  ligand  expression  may  be  due  to  ATR’s  influence  on  the 
transcription  factors  Specificity  Protein  (SP)1  and  SP3  resulting  in  ULBP-1  transcription  [101]. 
Induction of ULBP-1 and -2 by Vpr provides an activating signal for NK cells to degranulate [99,100]. 
Nef has also been implicated in down modulating ligands for the activating receptor NKG2D [102]. 
Namely, it was shown that Nef down modulates MIC-A, ULBP-1, and ULBP-2. However, in more 
recent study, deleting Nef from HIV-1 resulted in surface expression of NKG2D ligands to the same 
level as wild-type infected cells [99]. Furthermore, we were never able to detect MIC-A cell surface Viruses 2011, 3                         
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expression on HIV-1 infected primary CD4+ T-cells. The discrepancies between the two studies have 
yet to be determined.  
Figure  3.  HIV-1  Vpr  leads  to  expression  of  NKG2D  ligands,  unique  long  16-binding 
protein (ULBP)-1 and -2. Viral protein R, Vpr, bridges DCAF1, a substrate recognition 
factor for an E3 ubiquitin ligase system to an unknown cell cycle protein causing for the 
cell cycle protein to become ubiquitinated and destroyed. The degradation of the cell cycle 
protein induces phosphorylation of the DNA damage sensor ataxia telangiectasia-mutated 
and  Rad  3-related  (ATR),  which  in  turn  induces  expression  of  the  NKG2D  ligands,  
ULBP-1  and  -2.  Phosphorylation  of  ATR  also  leads  to  G2  cell  cycle  arrest  creating  a 
favorable environment for transcription of the HIV long terminal repeat (LTR). 
 
6.2. Nef down Modulates Ligands for Inhibitory Receptors on NK Cells 
It was reported over 20 years ago that HIV-1 down modulates MHC class I molecules [103]. It was 
later discovered that MHC class I down modulation was due to the HIV-1 protein negative regulatory 
factor (Nef) [104]. In subsequent studies, Nef was found to selectively down modulate the MHC class 
I molecules HLA-A and -B, but not HLA-C and -E [105]. Nef is a 27 kD protein expressed early in 
HIV-1 infection. Nef selectively down modulates HLA-A and -B by binding to two key residues  
(a tyrosine at position 321 and an aspartate at position 328) in the cytoplasmic tails of HLA-A and -B. 
These residues are not present in the cytoplasmic tail of HLA-C preventing Nef from down modulating 
HLA-C [105]. While HLA-E cytoplasmic tail has the two residues found in HLA-A and -B, Nef is 
incapable of down modulating HLA-E. Exchanging the cytoplasmic tail of HLA-E for the cytoplasmic 
tail  of  HLA-A  resulted  in  HLA-E’s  down  modulation,  indicating  that  the  cytoplasmic  tail  of  Viruses 2011, 3                         
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HLA-E differs in numerous other residues to HLA-A and -B preventing Nef from down modulating 
HLA-E [105,106].  
Upon binding to HLA-A and -B, Nef re-routes both MHC class I molecules from the trans-Golgi 
network (TGN) to endosomes by recruiting adaptor protein (AP)-1, a clathrin-mediated protein that 
facilitates trafficking between the TGN and endosomes [107] (Figure 4). The Nef/MHC-I complex 
binds  to  the    subunit  of  AP-1  [108–110].  Nef  then  recruits  coatomer  protein-1β  (-COP),  a 
component of COP-1 coats for transport through the early secretory pathways [111]. β-COP binds to 
an arginine motif (RXR) on the N-terminal of Nef [112]. Nef’s ability to bind to β-COP causes HLA-A 
and -B to be directed to lysosomes for their degradation. Additionally, Nef increases the internalization 
of  MHC-I  molecules  from  the  plasma  membrane  through  Nef’s  ability  to  utilize  PACS-1,  a 
phosphofurin acidic cluster sorting protein [113]. PACS-1 controls endosome to TGN trafficking by 
binding to acidic motifs of a protein and forms a bridge to AP-1. Nef contains a cluster of glutamic 
acids from residue 62-65 that binds with PACS-1 connecting Nef with AP-1 [114]. In this instance, 
Nef forces the endocytosis of HLA-A and -B into the TGN. However, recent studies have shown that 
Nef primarily acts to re-route HLA-A and -B from the TGN to lysosomes, instead of promoting the 
internalization of MHC-I molecules via the PACS-1 mechanism [107,115,116]. 
Figure 4. HLA-A and -B are down modulated by HIV Nef, removing an inhibitory signal 
for NK cells. HIV-1 Nef selectively down modulates HLA-A and -B, but leaves HLA-C 
and -E on the infected cell surface. Nef re-routes both HLA-A and -B from the TGN to 
endosomes and eventually to lysosomes for the degradation of the MHC-I molecules. Nef 
is able to bind to both the tail of the MHC-I molecules as well as the trafficking molecule, 
AP-1, to facilitate the transport of HLA-A and -B to the endosomes. Once in the endosome, 
Nef recruits β-COP for further transport into lysosomes. The down modulation of HLA-A 
and -B removes the inhibitory ligands for the NK cell inhibitory receptor KIR3DL2 and 
KIR3DL1, respectively. Yet, because Nef is unable to down modulate HLA-C and -E, NK 
cells expressing inhibitory receptors for these two MHC-I molecules will inhibit NK cell 
degranulation of HIV infected cells. 
 Viruses 2011, 3                         
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It was thought that the selectivity of Nef’s down modulation of only HLA-A and -B, and not  
HLA-C and -E, was necessary for HIV-1 to evade responses from NK cells [105]. However, as NK 
cell expression of iNKRs is variegated, there are a significant number of NK cells not expressing 
iNKRs to HLA-C and HLA-E [117]. Because of the difference in NK cell expression of iNKRs, it 
stands to reason that NK cells lacking iNKRs for HLA-C and HLA-E should efficiently lyse HIV-1 
infected T-cells due to Vpr’s induction of NKG2D ligands and Nef’s down modulation of HLA-A  
and -B. In fact, NK cells lacking iNKRs for HLA-C and -E are able to lyse HIV-1-infected cells when 
HLA-A and -B are down modulated [117]. These studies indicate that NK cells have the ability to kill  
HIV-1-infected cells. However, it should be noted that NK cell killing of HIV-1-infected cells is still 
two-thirds less than that observed with NK cell killing of the NK-sensitive cell line, K562 [117]. 
Furthermore, HIV-1 infected CD4+ T-cells have the capability to activate NK cells to the same extent 
as K562 cells, yet the infected T-cells induce NK cells to degranulate to a third of the level of NK cells 
exposed to K562 cells [118]. 
6.3. NK Cell Degranulation is Hindered by Down Modulation of NTB-A on HIV-1 Infected Cells by Vpu  
Why NK cells are activated but unable to degranulate in the presence of HIV-1 infected cells was a 
mystery  until  recent  work  illustrating  the  need  for  not  only  an  activating  receptor  but  also  a  
co-activating  receptor  to  be  engaged  for  NK  cell  degranulation  [42].  NK,  T-cell,  B-cell  antigen  
(NTB-A) is one such co-activating receptor that is expressed on all blood NK cells as well as CD4+  
T-cells [119]. In addition, NTB-A is down modulated on infected T-cells by HIV-1 [120,121].  
NTB-A is a type I transmembrane protein and a member of the signaling lymphocytic activation 
molecule (SLAM) receptor family [119]. It is a part of the Ig superfamily containing a distal V-type 
and a proximal C2-type domain in the extracellular portion of the receptor. NTB-A forms a homotypic 
ligand-receptor pair. When bound by its ligand, two of NTB-A’s three immunoreceptor tyrosine-based 
switch motifs (TXYXXV/I) are phosphorylated by tyrosine kinases such as Lck [43,122]. Phosphorylation 
of tyrosine 284 results in binding of Ewing’s sarcoma-activated transcript (EAT)-2, a SAP family 
member.  EAT-2  binding  to  NTB-A  has  been  implicated  in  cytokine  production  by  primary  NK  
cells [123]. Phosphorylation of tyrosine 319 results in SAP binding to NTB-A [63,124]. SAP then 
binds the protein kinase Fyn, which in turn, triggers NK cells degranulation [67]. While triggering 
NTB-A alone is insufficient to induce NK cells to release their granules, when triggered together with 
NKG2D, NK cells are able to degranulate [118].  
Since ligand binding of NTB-A on NK cells has been shown to induce NK cell cytotoxicity, it 
seems likely that HIV-1-infected cells down modulate NTB-A to evade NK cells. More specifically, 
recent  work  has  shown  the  HIV  accessory  protein  Vpu  to  be  both  necessary  and  sufficient  for  
NTB-A’s  down  modulation  [118].  Vpu’s  transmembrane  region  binds  to  NTB-A  and  sequesters  
NTB-A within the TGN [125]. Furthermore, Vpu does not increase the internalization of NTB-A and 
does not alter the steady-state levels of NTB-A expressed in the cell [118].  
Vpu’s down modulation of NTB-A is distinct from the down modulation of CD4 and tetherin/BST-2. 
For both CD4 and tetherin/BST-2, Vpu serves as an adaptor to β-TrCP, a human F box protein that 
serves  as  a  substrate  recognition  receptor  for  the  E3  ubiquitin  ligase  complex.  Phosphoserines  at 
positions 52 and 56 of Vpu are necessary for the interaction between β-TrCP and Vpu. Ubiquitinized Viruses 2011, 3                         
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CD4 is degraded by proteasomes, whereas ubiquitinized tetherin/BST-2 is transported  to acidified 
endosomes though this may not be the only mechanism of Vpu’s down modulation of tetherin/BST-2 
[126–132].  However,  this  is  not  the  case  with  Vpu’s  down  modulation  of  NTB-A.  Mutations  of  
the serine residues at position 52 and 56 result in down modulation of NTB-A to similar levels as wild-
type  Vpu.  Additionally,  NTB-A’s  association  with  Vpu  does  not  lead  to  its  degradation  by 
proteasomes nor is NTB-A trafficked to acidified endosomes for its destruction [118]. 
Thus, it is likely that NTB-A is unable to recycle back to the cell surface, removing the second 
activating signal needed to trigger NK cell degranulation. NTB-A’s down-modulation by Vpu prevents 
NK cell degranulation and lysis of HIV-1-infected T-cells by three-fold [118]. Interestingly, even in 
the presence of Vpu, NK cells expressing iNKRs for HLA-C and HLA-E were able to degranulate 
albeit two-fold less than NK cells not expressing iNKRs for HLA-C and HLA-E [118].  
7. Conclusion 
Our recent studies indicate that HIV-1 evades NK cells. It would seem likely that NK cells would 
be skewed toward killing infected cells since HIV-1 infection leads to increased expression of ICAMs 
on the infected cell surface [133], induces expression of ULBP-1 and ULBP-2, and down modulates 
HLA-A and HLA-B. However, Vpu’s down modulation of NTB-A and the retention of HLA-C and -E 
prevent efficient degranulation of NK cells (Figure 5). Future work needs to be conducted to better 
understand the mechanism through which Vpu down modulates NTB-A, and furthermore, why NTB-A, 
but not other co-activating ligands, is crucial for NK cell lysis of HIV-1-infected cells. 
Figure 5. HIV-1 Vpu’s down modulation of NTB-A prevents NK cells from efficiently 
killing infected cells. Though Vpr induces expression of ligands for the activating receptor 
NKG2D and Nef down modulates ligands for the NK cell inhibitory receptor, NK cells are 
still unable to efficiently lyse HIV infected CD4+ T-cells. Vpu’s sequestration of NTB-A 
in the trans-Golgi network in the infected cell prevents NK cells from obtaining a second 
activating signal to initiate NK cell degranulation. 
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